ProQR Therapeutics (NASDAQ:PRQR) Given "Buy" Rating at HC Wainwright

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report)'s stock had its "buy" rating reiterated by investment analysts at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $10.00 price objective on the biopharmaceutical company's stock. HC Wainwright's target price would indicate a potential upside of 203.95% from the company's previous close.

PRQR has been the topic of a number of other reports. Chardan Capital restated a "buy" rating and issued a $4.00 price objective on shares of ProQR Therapeutics in a research note on Thursday. StockNews.com cut ProQR Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, November 28th. Finally, Raymond James raised ProQR Therapeutics from an "outperform" rating to a "strong-buy" rating and increased their price objective for the stock from $6.00 to $14.00 in a research report on Tuesday, October 29th. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, ProQR Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $7.60.

ProQR Therapeutics Trading Down 2.7 %

Shares of ProQR Therapeutics stock traded down $0.09 during trading on Thursday, reaching $3.29. The company's stock had a trading volume of 554,479 shares, compared to its average volume of 520,463. The company has a 50-day moving average price of $3.36 and a two-hundred day moving average price of $2.38. ProQR Therapeutics has a fifty-two week low of $1.61 and a fifty-two week high of $4.62. The firm has a market cap of $268.73 million, a PE ratio of -10.50 and a beta of 0.24.

Institutional Investors Weigh In On ProQR Therapeutics

A number of institutional investors have recently added to or reduced their stakes in PRQR. BNP Paribas Financial Markets raised its stake in shares of ProQR Therapeutics by 14.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company's stock worth $107,000 after buying an additional 7,300 shares in the last quarter. OneDigital Investment Advisors LLC grew its holdings in ProQR Therapeutics by 37.0% during the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company's stock worth $105,000 after acquiring an additional 15,550 shares during the period. Finally, Privium Fund Management B.V. raised its position in ProQR Therapeutics by 0.9% in the third quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company's stock worth $10,251,000 after acquiring an additional 51,663 shares in the last quarter. Hedge funds and other institutional investors own 32.65% of the company's stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).